GBI Research, Jan 2012, Pages: 99
with an emphasis on safety and efficacy details, Phase II and Phase III clinicaltrial analysis for both completed and ongoing clinicaltrials, most promising drugs with more emphasis on safety, efficacy
GBI Research, Jan 2012, Pages: 152
of the major marketed cardiovascular drugs, with an emphasis on safety and efficacy details, Phase II and Phase III clinicaltrial analysis for both completed and ongoing clinicaltrials, the most promising
GBI Research, Feb 2012, Pages: 135
in autoimmune disorders. The report examines different aspects of clinicaltrial endpoints in autoimmune disorders, such as analysis of major marketed autoimmune drugs with an emphasis on safety and efficacy
GBI Research, Nov 2011, Pages: 216
with an emphasis on safety and efficacy details. Phase II and Phase III clinicaltrial analysis for both completed and ongoing clinicaltrials, most promising central nervous system drugs with details on safety
GBI Research, Jan 2012, Pages: 118
clinicaltrials. The report examines different aspects of clinicaltrial endpoints in orphan diseases, such as analysis of major marketed orphan drugs with an emphasis on safety and efficacy details, Phase
GBI Research, July 2011, Pages: 72
during the course of clinicaltrials, due to safety and efficacy issues. The decision to discontinue the development of a drug is taken by the health authorities and is based on interim analysis
Decision Resources, Inc., Nov 2011
to limit cardiovascular risk?
Scope:
- Regulatory environment: The FDA and the International Conference on Harmonisation guidelines, preclinical and clinical cardiac safetyassessments.
- Postmarketing
Business Insights, Nov 2010, Pages: 129
of compounds.
- Assess how the FDA’s draft guidelines on adaptive trials are influencing companies to use adaptive trials in their drug development programs.
- Evaluate the providers of key skills
FirstLine Consulting Group, Feb 2009, Pages: 47
Can Denosumab Achieve Superiority For The Prevention Of SREs In Cancer? There are many large clinicaltrials currently being conducted with denosumab. It is being tested in osteoporosis, treatment
FirstLine Consulting Group, Sep 2009, Pages: 37
of the trial. In our analysis, we have:
- Researched bapineuzumab phase I and phase II results in depth, and collected vast amounts of information that have helped us assess the true risk to safety
GBI Research, Sep 2011, Pages: 119
or acquisition activities, or due to a revision of its existing product pipeline. Other causes for the termination of deals included negative results in clinicaltrials designed to evaluate the safety and efficacy
Espicom Business Intelligence Ltd, Feb 2011, Pages: 102
combination, Contrave. The market was then surprised when the FDA did not approve the drug, asking instead for further clinicaltrials. If Contrave had been approved, it would have been the first new
Arrowhead Publishers, March 2007, Pages: 149
discovery process by identifying failures at an earlier stage.
This report provides detailed information regarding new developments in the field of clinicaltrials as well as an assessment of the impact
Decision Resources, Inc., March 2011, Pages: 22
biomarker programs alongside drug discovery and development because biomarkers can aid in discovery of drug targets, assessdrugsafety and efficacy, stratify patients in clinicaltrials, and facilitate go
Business Insights, April 2010, Pages: 178
reduce the attrition rate of late stage clinicaltrials by assessingdrug potential in terms of efficacy and toxicity at the early stages of the clinical development. Thus, biomarkers significantly
MP Advisors, Aug 2011
comparison major anticoagulants in DVT treatment
- Clinical Data comparison major anticoagulants in ACS Liver Toxicity
Long term safety concern: Liver Toxicity
Assessment of Bleeding Risk
- Clinical Data
Datamonitor, May 2011, Pages: 40
and target product profiles necessary for success in the obesity market
- Assess the challenges faced in treating obesity and the future direction for obesity therapy
- Provide insight into clinicaltrial
Business Insights, April 2009, Pages: 159
rare events that are unlikely to be identified in clinicaltrials. Major pharma companies have subsequently begun to implement an array of new technologies for drugsafety prediction into the discovery
